Citigroup
UTMD icon

Citigroup’s Utah Medical Products UTMD Stock Holding History

Citigroup’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.4K Buy
700
+564
+415% +$35.5K ﹤0.01% 4579
2025
Q4 		$7.61K Sell
136
-50
-27% -$2.9K ﹤0.01% 5135
2025
Q3 		$11.7K Sell
186
-1,970
-91% -$117K ﹤0.01% 4975
2025
Q2 		$123K Sell
2,156
-1,570
-42% -$85.4K ﹤0.01% 4310
2025
Q1 		$209K Buy
3,726
+92
+3% +$5.51K ﹤0.01% 4176
2024
Q4 		$223K Sell
3,634
-1,527
-30% -$98.7K ﹤0.01% 4352
2024
Q3 		$345K Buy
5,161
+3,941
+323% +$268K ﹤0.01% 3974
2024
Q2 		$81.5K Buy
1,220
+620
+103% +$42.2K ﹤0.01% 4318
2024
Q1 		$42.7K Hold
600
– – ﹤0.01% 4699
2023
Q4 		$50.5K Buy
600
+494
+466% +$41K ﹤0.01% 4515
2023
Q3 		$9.12K Sell
106
-975
-90% -$90K ﹤0.01% 4565
2023
Q2 		$101K Buy
1,081
+1,078
+35,933% +$102K ﹤0.01% 4245
2023
Q1 		$285 Sell
3
-168
-98% -$15.4K ﹤0.01% 5240
2022
Q4 		$17.2K Buy
171
+64
+60% +$5.84K ﹤0.01% 4653
2022
Q3 		$9K Sell
107
-121
-53% -$10.7K ﹤0.01% 5041
2022
Q2 		$20K Buy
228
+66
+41% +$5.63K ﹤0.01% 5013
2022
Q1 		$15K Sell
162
-721
-82% -$66.3K ﹤0.01% 5335
2021
Q4 		$88K Buy
883
+601
+213% +$61.3K ﹤0.01% 4795
2021
Q3 		$26K Buy
282
+110
+64% +$9.72K ﹤0.01% 5115
2021
Q2 		$15K Sell
172
-65
-27% -$5.62K ﹤0.01% 5481
2021
Q1 		$21K Sell
237
-438
-65% -$38.5K ﹤0.01% 5238
2020
Q4 		$57K Buy
675
+501
+288% +$42.7K ﹤0.01% 5949
2020
Q3 		$14K Sell
174
-4,878
-97% -$405K ﹤0.01% 6424
2020
Q2 		$448K Buy
5,052
+4,008
+384% +$360K ﹤0.01% 4359
2020
Q1 		$98K Buy
1,044
+337
+48% +$31.3K ﹤0.01% 5359
2019
Q4 		$76K Buy
707
+233
+49% +$23.6K ﹤0.01% 5991
2019
Q3 		$45K Sell
474
-488
-51% -$45.4K ﹤0.01% 6194
2019
Q2 		$92K Buy
962
+157
+20% +$13.2K ﹤0.01% 5952
2019
Q1 		$71K Sell
805
-37
-4% -$3.25K ﹤0.01% 6059
2018
Q4 		$70K Buy
842
+7
+0.8% +$616 ﹤0.01% 5954
2018
Q3 		$78K Buy
835
+420
+101% +$40.1K ﹤0.01% 6136
2018
Q2 		$46K Sell
415
-3,856
-90% -$403K ﹤0.01% 6357
2018
Q1 		$422K Sell
4,271
-1,300
-23% -$116K ﹤0.01% 4170
2017
Q4 		$454K Buy
5,571
+1,936
+53% +$151K ﹤0.01% 4205
2017
Q3 		$268K Sell
3,635
-115
-3% -$8.27K ﹤0.01% 4730
2017
Q2 		$272K Buy
3,750
+541
+17% +$35.6K ﹤0.01% 4529
2017
Q1 		$200K Sell
3,209
-2,350
-42% -$148K ﹤0.01% 4655
2016
Q4 		$404K Buy
5,559
+2,992
+117% +$195K ﹤0.01% 4607
2016
Q3 		$154K Buy
2,567
+1,150
+81% +$73.2K ﹤0.01% 4879
2016
Q2 		$89K Sell
1,417
-1,723
-55% -$111K ﹤0.01% 5172
2016
Q1 		$196K Buy
3,140
+233
+8% +$13.7K ﹤0.01% 5111
2015
Q4 		$170K Buy
2,907
+1,306
+82% +$74.1K ﹤0.01% 4895
2015
Q3 		$86K Sell
1,601
-564
-26% -$30.8K ﹤0.01% 5074
2015
Q2 		$129K Buy
2,165
+1,959
+951% +$110K ﹤0.01% 4805
2015
Q1 		$12K Sell
206
-439
-68% -$25.8K ﹤0.01% 6382
2014
Q4 		$39K Buy
645
+513
+389% +$28.4K ﹤0.01% 5855
2014
Q3 		$6K Buy
132
+15
+13% +$762 ﹤0.01% 6505
2014
Q2 		$6K Sell
117
-1,865
-94% -$95.8K ﹤0.01% 6395
2014
Q1 		$115K Buy
1,982
+381
+24% +$20.8K ﹤0.01% 4865
2013
Q4 		$91K Buy
1,601
+1,593
+19,913% +$87.4K ﹤0.01% 5317
2013
Q3 		$0 Buy
8
+4
+100% +$218 ﹤0.01% 6997
2013
Q2 		$0 Buy
+4
New +$188 ﹤0.01% 6798

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's UTMD Position: Q1 2026 in Review

Citigroup increased its Utah Medical Products (UTMD) stake by 415% in Q1 2026, buying an estimated $35.5K and bringing the position to 700 shares worth $43.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4579.

Citigroup first reported a position in UTMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $454K in Q4 2017. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Citigroup held 700 shares of Utah Medical Products worth $43.4K as of Q1 2026.
  • Citigroup bought 564 Utah Medical Products shares in Q1 2026, an estimated $35.5K.
  • Utah Medical Products made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4579 holding.
  • Citigroup first reported a position in Utah Medical Products in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Utah Medical Products position peaked at $454K in Q4 2017.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.